BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat

Reuters12-09

Dec 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:

AGIOS PRESENTS POSITIVE RESULTS FROM PHASE 3 ENERGIZE-T STUDY OF MITAPIVAT AT ASH 2024 AND PROVIDES REGULATORY UPDATE ON MITAPIVAT
AGIOS PHARMACEUTICALS - FILED REGULATORY APPLICATIONS FOR MITAPIVAT US, EU, SAUDI ARABIA ,UAE

Source text: ID:nGNXZTXPq

Further company coverage: AGIO.O

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490753275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 01:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490753275","market":"us","top_or_hot":-1,"title":"BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Agios Pharmaceuticals Inc <span>AGIO.O</span>:</p><ul><li><p>AGIOS PRESENTS POSITIVE RESULTS FROM PHASE 3 ENERGIZE-T STUDY OF MITAPIVAT AT ASH 2024 AND PROVIDES REGULATORY UPDATE ON MITAPIVAT</p></li><li><p>AGIOS PHARMACEUTICALS - FILED REGULATORY APPLICATIONS FOR MITAPIVAT US, EU, SAUDI ARABIA ,UAE</p></li></ul><p>Source text: <span>ID:nGNXZTXPq</span></p><p>Further company coverage: <span>AGIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 01:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On MitapivatDec 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:AGIOS ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUA7S5CHD:1","article_id":"2490753275","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490753275","pubTimestamp":1733679763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of MitapivatAt Ash 2024 And Provides Regulatory Update On MitapivatDec 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:AGIOS PRESENTS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"简介-Agios在Ash 2024上展示了mitapivat 3期ENERIZE-T研究的积极结果，并提供了Mitapivat的监管更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":0.9},"content_text":"BRIEF-Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On MitapivatDec 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:AGIOS PRESENTS POSITIVE RESULTS FROM PHASE 3 ENERGIZE-T STUDY OF MITAPIVAT AT ASH 2024 AND PROVIDES REGULATORY UPDATE ON MITAPIVATAGIOS PHARMACEUTICALS - FILED REGULATORY APPLICATIONS FOR MITAPIVAT US, EU, SAUDI ARABIA ,UAESource text: ID:nGNXZTXPqFurther company coverage: AGIO.O ((Reuters.Briefs@thomsonreuters.com;;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490753275"}